Laurion Capital Management LP Takes Position in Illumina, Inc. (NASDAQ:ILMN)

Laurion Capital Management LP bought a new stake in Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 7,112 shares of the life sciences company’s stock, valued at approximately $950,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Bleakley Financial Group LLC bought a new stake in shares of Illumina in the 4th quarter valued at about $751,000. Van ECK Associates Corp raised its holdings in shares of Illumina by 17.5% in the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock valued at $20,347,000 after purchasing an additional 22,718 shares during the period. Strategic Financial Concepts LLC bought a new stake in shares of Illumina in the 4th quarter valued at about $1,464,000. Allworth Financial LP raised its holdings in shares of Illumina by 720.7% in the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock valued at $1,001,000 after purchasing an additional 6,263 shares during the period. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of Illumina in the 4th quarter valued at about $448,000. 89.42% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ILMN has been the topic of several research analyst reports. Robert W. Baird lowered their price target on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday, March 5th. Barclays lowered their price target on shares of Illumina from $100.00 to $77.00 and set an “underweight” rating on the stock in a report on Thursday, April 10th. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and lowered their price target for the company from $177.00 to $140.00 in a report on Friday, February 7th. Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. Finally, Citigroup lowered their price target on shares of Illumina from $90.00 to $85.00 and set a “neutral” rating on the stock in a report on Monday, April 7th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina currently has an average rating of “Moderate Buy” and an average target price of $133.00.

Illumina Stock Performance

NASDAQ ILMN opened at $75.76 on Monday. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $11.99 billion, a price-to-earnings ratio of -9.86, a P/E/G ratio of 1.60 and a beta of 1.35. The firm’s 50 day simple moving average is $78.94 and its 200 day simple moving average is $113.12. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.01. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter last year, the business posted $0.98 EPS. As a group, research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.